Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 84

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 3
Chunk 84
---
872 15,260 Research and development12,791 7,675 6,510 Acquired IPR&D and milestones2,757 778 697 Other operating expense (income), net(7)(179)56 Total operating costs and expenses47,197 41,561 39,937 Operating earnings9,137 12,757 18,117 Interest expense, net2,160 1,684 2,044 Net foreign exchange loss21 146 148 Other expense, net3,240 4,677 2,448 Earnings before income tax expense3,716 6,250 13,477 Income tax expense (benefit)(570)1,377 1,632 Net earnings4,286 4,873 11,845 Net earnings attributable to noncontrolling interest8 10 9 Net earnings attributable to AbbVie Inc.$4,278 $4,863 $11,836 Per share dataBasic earnings per share attributable to AbbVie Inc.$2.40 $2.73 $6.65 Diluted earnings per share attributable to AbbVie Inc.$2.39 $2.72 $6.63 Weighted-average basic shares outstanding1,769 1,768 1,771 Weighted-average diluted shares outstanding1,773 1,773 1,778 

The accompanying notes are an integral part of these consolidated financial statements.

51     |  2024 Form 10-K

AbbVie Inc. and Subsidiaries

Consolidated Statements of Comprehensive Income 

years ended December 31 (in millions)202420232022Net earnings$4,286 $4,873 $11,845 Foreign currency translation adjustments, net of tax expense (benefit) of $(39) in 2024, $15 in 2023 and $(10) in 2022(1,008)407 (943)Net investment hedging activities, net of tax expense (benefit) of $133 in 2024, $(109) in 2023 and $152 in 2022484 (399)555 Pension and post-employment benefits, net of tax expense (benefit) of $206 in 2024, $(6) in 2023 and $272 in 2022824 (30)1,088